Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.
McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference. McGee J, et al. Among authors: berek j. Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010. Ann Oncol. 2017. PMID: 28119296 Free article.
Abagovomab for ovarian cancer.
Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, du Bois A. Pfisterer J, et al. Among authors: berek j. Expert Opin Biol Ther. 2011 Mar;11(3):395-403. doi: 10.1517/14712598.2011.553598. Epub 2011 Jan 18. Expert Opin Biol Ther. 2011. PMID: 21241213 Review.
First-line therapy in ovarian cancer trials.
Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Thigpen T, et al. Among authors: berek j. Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d. Int J Gynecol Cancer. 2011. PMID: 21543937 Review.
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.
Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G; GCIG Endometrial Cancer Clinical Trials Planning Meeting. Creutzberg CL, et al. Int J Gynecol Cancer. 2013 Oct;23(8):1528-34. doi: 10.1097/IGC.0b013e3182a26edb. Int J Gynecol Cancer. 2013. PMID: 24257568
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Roncolato FT, et al. Among authors: berek j. Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26. Gynecol Oncol. 2018. PMID: 29107348 Free article.
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML. Roncolato FT, et al. Among authors: berek j. Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10. Gynecol Oncol. 2020. PMID: 31836184
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Vergote I, et al. Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr, Miller A, Concin N, Powell MA, Stuart G, Bookman MA; participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research. Creutzberg CL, et al. Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. Lancet Oncol. 2024. PMID: 39214113
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
352 results